Please ensure Javascript is enabled for purposes of website accessibility

FDA Yanks 1 Drug From the Market

By Brenton Flynn - Updated Apr 7, 2017 at 12:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA has pulled Teva Pharmaceuticals' (TEVA 0.91%) generic version of antidepressant drug Wellbutrin from the market. The issue is not one of safety, but efficacy, as Teva's 300mg generic fails to meet the bioequivalence of the original branded version, which is marketed by Valent Pharamaceuticals (BHC 20.36%). The 150mg dosage of the drug performs as required and will not be affected.

If instances like this lead the FDA to reassess the generic approval process, it would be good news for branded pharma, in general, and bad news for generics. Raising the hurdle for generic bioequivalence could mean discount-drug cost spikes down the line. For the full story and analyst Brenton Flynn's take on the issue, check out the video below.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.74 (0.91%) $0.07
Viatris Inc. Stock Quote
Viatris Inc.
Allergan plc Stock Quote
Allergan plc
Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$8.75 (20.36%) $1.48
Impax Laboratories, Inc. Stock Quote
Impax Laboratories, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.